Majella E. Lane
`School of Pharmacy
`Senior Lecturer, Director of the Skin Research Group
`October 1st 2008
`
`
`Curriculum Vitae
`
`
`1. Personal Details
`Name:
`Department:
`Present appointment:
`Date of appointment:
`
`
`
`2. Education/Qualifications
`Dates
`Detail of degree; diploma; other qualification
`1992
`B.Sc. (Pharm.), First Class. Gold medallist.
`1994
`Diploma in Statistics
`1995
`Diploma in Management
`1997
`Ph.D.
`
`
`
`3. Professional History (in chronological order)
`Dates
`Detail of position held
`01/10/1995
`Lecturer in Pharmaceutical Chemistry
`1/10/1997
`Lecturer in Pharmaceutics
`1/10/1998
`Director, M.Sc. Pharmaceutical Technology
`1/10/2005
`Lecturer in Pharmaceutics
`
`
`1/10/2008
`Senior Lecturer in Pharmaceutics
`
`
`1/10/2010
`Director, Skin Research Group
`
`Institution
`Trinity College, Dublin
`Trinity College, Dublin
`Trinity College, Dublin
`Trinity College, Dublin
`
`
`Institution
`Trinity College, Dublin
`Trinity College, Dublin
`Trinity College, Dublin
`School of Pharmacy, University of
`London
`School of Pharmacy, University
`College London
`School of Pharmacy, University
`College London
`
`
`
`4. Other Appointments and Affiliations
`
`Extra ordinary Professor in Pharmaceutical Sciences, Northwest University Potchefstroom
`South Africa
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Page 1
`
`Anacor Exhibit 2045
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00170
`
`

`

`5. Prizes, Awards and other Honours:
`Detail of prize, award or honour
`Dates
`1990
`Foundation Scholarship
`
`
`1992
`University Gold medal
`
`
`1992
`Janssen Medal
`
`
`1992
`Wellcome Medal
`
`
`1992
`EOLAS Basic Research Award
`
`
`1994
`Best poster award
`
`
`
`
`1997
`Best poster award
`
`
`
`
`1998
`Mendell Award, 17th Pharmaceutical
`
`Technology Conference, Dublin
`
`
`2007
`Best paper, Best poster (Graduate awards)
`
`
`
`Awarding/electing body
`Trinity College, Dublin
`
`Trinity College, Dublin
`
`Janssen Ltd, Belgium
`
`Glaxo Smith Kline, Ireland
`
`Eolas, Ireland
`
`European Federation for
`Pharmaceutical Sciences
`
`American Association of
`Pharmaceutical Scientists
`
`Mendell Ltd.
`
`
`Skin Forum, UK.
`
`
`
`
`
`
`
`
`Page 2
`
`Anacor Exhibit 2045
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00170
`
`

`

`6. Grants:
`Elan Pharma (Ireland) IR Pounds 120,000 (1998)
`Provost’s Academic Development Fund, Trinity College, Dublin IR Pounds 32,000 (1999)
`Rice Steele Ltd (Ireland) IR Pounds 75,000 (2000)
`Fulbright Travel Award Ireland – USA. IR Pounds 16,000 (2002)
`EPSRC EP/D50273X/1 £180,049 (2005)
`Maruho Ltd. (Japan) £112,000 (2006)
`EPSRC Doctoral Training Award £65,000 (2007)
`Portuguese Science Foundation (FCT) £83,400 (2007)
`Acrux Ltd. (Australia) £86,500 (2007)
`International Islamic University (Malyasia) £102,000 (2008)
`Procter & Gamble (UK) £92,000 (2008)
`Croda Ltd. (UK) £105,000 (2009)
`Glaxo Smith Kline (UK) £85,000 (2009)
`ISP Ltd. (USA) £36,000 (2009).
`Higher Education Ministry (Syria) £86,000 (2009).
`Shiseido Ltd. (Japan) £106,000 (2009)
`Bloomsbury Studentship, Bloomsbury Colleges (UK) £52,000 (2009)
`British Council Scholarship £103,000 (2010)
`Dermal Ltd. (UK) £45,000. (2010)
`Procter & Gamble (UK) £45,000. (2011)
`Higher Education Department. (Iraq) £88,000 (2011)
`Dermal Ltd. (UK) £12,500. (2011)
`Higher Education Ministry (Malaysia) £116,500 (2012)
`DSM Ltd. (Switzerland) £46,000 (2012)
`Dermal Ltd. (UK) £12,500 (2012)
`Gojo Ltd. (USA ) £46,000 (2013)
`Glaxo Smith Kline (USA) £109,000 (2013)
`EPSRC Doctoral Training Award £109,000 (2013)
`Phospholipid Research Institute (Germany) £19,000 (2014)
`EPSRC Case Award £120,000 (2015)
`DSM Ltd. (Switzerland) £95,000 (2015)
`Glaxo Smith Kline (USA) £223,045 (2016)
`EPSRC Case Award £112,580 (2016)
`
`
`
`
`
`
`
`The reputation of the laboratory has attracted graduate students and PDRAs with fellowship
`funding from their home governments and institutions (including Bangladesh, Egypt, India, Iran,
`Iraq, Japan, Lithuania, Malaysia, Norway, Pakistan, Portugal, South Africa, Spain, and Syria).
`
`
`
`
`
`
`
`
`
`
`
`
`
`Page 3
`
`Anacor Exhibit 2045
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00170
`
`

`

`
`
`7. Invited talks:
`Details
`Date
`
`
`1998
`European Federation of Pharmaceutical Sciences Annual Meeting, Milan, Italy
`17th Pharmaceutical Technology Conference, Dublin, Ireland.
`1998
`Elan Pharma, Dublin, Ireland
`1998
`12th International Symposium on Microencapsulation, London, U.K.
`1999
`2000
`Controlled Release Society: Novel Vaccine Formulations, Dublin, Ireland
`2000
`American Association of Pharmaceutical Scientists Annual Meeting, Texas, USA.
`2002
`American Association of Pharmaceutical Scientists Annual Meeting, Toronto, USA
`2003
`Department of Pharmaceutical Sciences, University of Michigan, USA
`2003
`14th International Symposium on Microencapsulation, Singapore
`2004
`1st European Conf. Drug Delivery &Pharmaceutical Technology, Seville, Spain
`2004
`PharmSci Fair, Nice, France
`2005
`Wyeth Pharma, Havant U.K.
`2005
`15th International Symposium on Microencapsulation, Parma, Italy
`2005
`United Kingdom-Ireland Controlled Release Annual Meeting, Loughborough, UK
`2006
`Society of the Chemical Industry, London, UK
`2006
`North West University, Potchefstroom, South Africa
`2006
`Chulongkorn University, Thailand
`2006
`Department of Pharmaceutical Technology, Parma, Italy
`2007
`DTL Ltd. UK
`2007
`Universidad Nacional de Quilmes, Buenos Aires, Argentina
`2008
`University of Tromso, Norway
`2008
`Maruho Ltd., Kyoto, Japan
`2009
`Teikoku Pharma, Sanbonmatsu, Japan
`2009
`Josei University, Japan
`2010
`Swedish Academy of Pharmaceutical Sciences, Stockholm, Sweden
`2010
`University of Helsinki, Finland
`2010
`Faculty of Chemical and Pharmaceutical Science, University of Chile
`2011
`Lohmann Therapie-Systeme, Andernach, Germany
`2011
`Division of Chemistry, Sheffield Hallam University
`2011
`Society of Cosmetic Chemists, London, UK
`2011
`Controlled Release Society Annual Symposium, National Harbor, USA
`2011
`UK PharmSci, Nottingham, UK
`2011
`Glaxo Smith Kline, UK
`2012
`Stiefel, USA
`2012
`University of North Carolina, Chapel Hill, USA
`2012
`International Conference and Workshop on Biological Barriers, Saarland, Germany
`2012
`The anti-aging skin care conference, London UK
`2012
`Society of the Chemical Industry, London, UK
`2012
`Oriflame, Ireland
`2013
`PQRI, Washington, USA
`2013
`Cranfield University, UK
`2013
`Skin Forum, UK
`2013
`University of Vienna, Austria
`2013
`Reckitt Benckiser, UK
`2013
`Syngenta, UK
`2013
`UKPharmSci, Edinburgh, UK
`2013
`Phospholipid Research Centre, Heidelberg, Germany
`2013
`SCS Formulate, UK
`2013
`Avon, USA
`2014
`Almirall, Barcelona, Spain
`
`Page 4
`
`Anacor Exhibit 2045
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00170
`
`

`

`Biospain, Santiago de Compostela, Spain
`2014
`Phospholipid Research Centre, Braunschweig, Germany
`2014
`Infrared and Raman Discussion Group Meeting, Astra Zeneca, UK
`2014
`3rd Intl. Conference on Nutraceutical & Pharmaceutical Sciences, Tokyo, Japan
`2014
`2014
`Gattefossé, St Priest, France
`2015
`University of Coleraine, UK
`2015
`Interpharm, Chester, UK
`2015
`Barrier function of mammalian skin. Gordon Research Conference, USA
`2015
`International Federation of Societies of Cosmetic Chemists, Zurich, Switzerland
`2015
`Society of Cosmetic Scientists, Formulate, Coventry, UK
`2015
`Reckitt Benckiser, UK
`2016
`Brazilian Cosmetic Society, Sao Paulo
`2016
`Occupational and Environmental Exposure of Skin to Chemicals, Manchester
`2017
`In Cosmetics, London, UK
`2017
`TRI, Princeton, New Jersey, USA
`2018
`11th World Meeting on Pharmaceutics, Granada, Spain
`2018
`Future of Formulations in Cosmetics, Barcelona, Spain
`2018
`APV-Skin Forum Joint Meeting, Tallinn, Estonia
`
`
`8. Academic supervision:
`
`PhD
`Date
`
`2002
`2003
`2004
`2008
`2010
`2011
`2011
`2012
`2012
`2012
`2013
`2013
`2014
`2014
`2014
`2015
`2015
`2015
`2016
`2016
`2016
`2016
`2016
`2017
`2017
`
`Details
`
`Fiona Sheena Brennan
`Karl Alexander Levis
`Mark Hanlon
`Paulo Santos
`Gabriela Oliveira
`Sonal Chavda
`Kazumasa Hirata
`Diar Mohammed
`Hazrina Ab-Hadi
`Mihaela Gorcea
`Rita Isabel Henrique Neves Vieira
`Marta Machado
`Rita Mateus
`Haydar M. Abdalghafor
`Fouad Helal
`Tasnuva Haque
`Anna Duzynska
`Mohammed Sattar
`Parisi, Nicola
`Choon Fu, Goh
`Nidhin Raj
`Avnish Patel
`Lin Luo
`Nicolas Brand
`Jennifer Chang
`
`
`
`
`
`
`
`
`Page 5
`
`Anacor Exhibit 2045
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00170
`
`

`

`Current PhD students
`
`Paz, Miguel
`
`
`Guneri, Dilek
`
`
`Zhang, Yanling
`
`
`Kung, Chin-Ping
`
`
`Iliopoulos, Fotis
`
`
`Sherif, Solomon
`
`Monjur-Al-Hossain, A.S.M.
`
`MSc. in Pharmaceutical Technology
`McBride, Bryan
`
`Trinity College, Dublin 2000
`Farrell, Lisa
`
`Trinity College, Dublin 2001
`Manning, Robert Emmet Trinity College, Dublin 2001
`Walsh, Patricia Geraldine Trinity College, Dublin 2001
`Curran, Gemma
`
`Trinity College, Dublin 2001
`Whelan, Deirdre Ann
`Trinity College, Dublin 2001
`Nghiem, Xuan-Tien
`Trinity College, Dublin 2003
`Lewis, Gareth
`
`Trinity College, Dublin 2003
`Tambuwala, Murtaza
`Trinity College, Dublin 2004
`Coppins, Jennifer
`
`Trinity College, Dublin 2004
`McCormack, Yvonne
`Trinity College, Dublin 2005
`Kieran, Aisling
`
`Trinity College, Dublin 2005
`McGrath, Caoimhe
`Trinity College, Dublin 2005
`Amezua, Patricia
`
`Trinity College, Dublin 2005
`Hughes, Robert
`
`Trinity College, Dublin 2005
`Dey, Cinmoy
`
`Trinity College, Dublin 2005
`
`MSc. In Drug Delivery
`Ahlan, Mohammed
`Ogawa, Chinedu
`
`Gambar, Garima
`
`Desai, Shefali
`
`Ab-Hadi, Hazrina
`
`Zhang, Ying
`
`Abghalfor, Haydar
`
`Purohit, Pallavi
`
`Tewi, Shweta
`
`Makary, Patrick
`
`Omar, Mahmoud
`
`Madaan, Shivam
`
`Lv, Junting
`
`
`Lu, Zhao
`
`
`
`
`M.Res.
`Luo, Lin
`
`
`
`University of London, 2006
`University of London, 2006
`University of London, 2008
`University of London, 2008
`University of London, 2008
`University of London, 2009
`University of London,.2009
`University of London, 2011
`University of London, 2011
`University College London, 2012
`University College London, 2012
`University College London, 2013
`University College London, 2016
`Univetrsity College London 2016
`
`
`
`
`
`University of London, 2012
`
`
`
`Page 6
`
`Anacor Exhibit 2045
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00170
`
`

`

`9. Research career activity:
`My research philosophy can be expressed as “To understand and characterise the transport of
`actives and excipients across membranes to enable the improved design of pharmaceutical,
`cosmetic and veterinary formulations.” Principally this has been achieved by my expertise in the
`area of in vitro and in vivo models of the biological membranes which are the major barriers to
`drug delivery. The areas of activity may be broken down as follows:
`
`
`
`
`
`
`
`
`
`
`1. Establishment of in vitro and in vivo models of the nail, skin, buccal epithelium and to a
`lesser extent, the small intestine, for the study of drug transport. I have identified human
`tissue sources within the UK and externally. Full National Health Service ethical approval
`for storage and use of such tissue has been awarded. Validated models for skin and
`buccal transport have been established. I frequently host visiting scientists from the EU
`and Asia who wish to develop expertise in these models. This has also allowed
`participation in EU networks with collaborators who recognise my group as a centre of
`excellence for membrane transport studies. In November 2015 I was appointed to the
`Chemistry, Pharmacy and Standards committee of the Commission on Human Medicines
`because of my reputation as an expert in topical and transdermal delivery.
`
`
`2. Characterisation of biological membranes. Model membranes and human nails and skin
`are characterised by the research group using a range of techniques, principally Franz cell
`diffusion experiments, Attenuated Total Reflectance Infra Red Spectroscopy, Trans
`Epidermal Water Loss (TEWL) and impedance measurements. Knowledge of the barrier
`function of the membrane permits an understanding of how materials permeate and will
`indicate whether the partition or diffusion behaviour of the material dominates its transport
`characteristics. More recently we have developed Confocal Raman spectroscopy to probe
`the influence of excipients on drug disposition in skin in humans in vivo.
`
`3. In addition to the biophysical tools which we currently use to assess skin barrier function,
`the activity of proteases responsible for skin desquamation may potentially be a useful
`marker of skin competence. To this end I have developed and validated novel assays for
`the measurement of epidermal turnover, inflammation and barrier integrity of human skin.
`The long-term goal will be to identify markers which advance our understanding of why
`patient response to topical treatments and therapeutic interventions varies markedly
`across the population. The methods are also of interest to dermatologists with a view to
`developing minimally invasive diagnostic methods for common skin diseases. Full ethical
`approval has been obtained for studies in human subjects.
`
`4. In collaboration with Professor Mohammed Ghavami and Dr Perry Xiao of London South
`Bank University, I propose to develop the in vivo measurement capability of the technique
`of Opto-Thermal Transient Emission Radiometry (OTTER) and Ultra Wide Band (UWB)
`processing. These techniques are fast, non-contacting, non-destructive and insensitive to
`small movements. The initial aims are to validate UWB measurements of healthy skin
`along with OTTER, and a longer term objective is to investigate the applications of UWB in
`the diagnosis of skin diseases. A grant application is currently in preparation for this work
`programme which will shortly be submitted to the EPSRC. Other collaborations include
`Department of Dermatology, University of Edinburgh, Blizard Institute (Queen Mary
`University London), Department of Immunology (Imperial College) and Palliative Care
`(Great Ormond Street Hospital).
`
`Page 7
`
`Anacor Exhibit 2045
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00170
`
`

`

`
`
`10. Teaching career summary / activity
`I teach across all years of the MPharm programme and also teach on taught MSc programmes
`
`Year 1: Topical and Transdermal Preparations
`
`Year 2: Skin structure and common skin diseases
`
`Year 3: Module leader and teacher for Drug Delivery Across Biological Barriers
`
`Year 3: Workshops on acne, eczema and psoriasis
`
`Year 3: Workshop on how to critique a research paper. I designed the workshop in 2015 and it
`aims to show students how to evaluate a research paper. It has proved extremely popular since its
`introduction and has provoked much debate amongst the student body.
`
`Year 4: Final project supervisor for a minimum of 3 students
`
`Each year I supervise a minimum of 5 M.Sc. students for a laboratory project. Because of the
`popularity of my research with the M.Sc. students, places in my group are often over-subscribed. I
`have already been approached by MSc students who wish to conduct their projects with me in
`2019.
`
` was nominated for a UCLU teaching award in 2013 and 2018.
`
`2012.
`in
`a Provost’s Teaching Award
`received
`I
`colleagues
`Together with
`(https://www.ucl.ac.uk/teaching-learning/awards-funding/provosts-teaching-awards/winners-2012)
`
`11. Knowledge Transfer / Exchange activity
`
`Because of my reputation in the areas of skin and buccal delivery the following companies have
`supported PhD studentships in my laboratory:
`
`
` Acrux Ltd. (Australia)
` Croda (UK)
` Diomed (UK)
` DSM Ltd. (Switzerland)
` Glaxo Smith Kline (UK)
` Gojo (USA)
`ISP (USA)
`
` Procter & Gamble (UK)
` Unilever (UK)
`
` I
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Page 8
`
`Anacor Exhibit 2045
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00170
`
`

`

`I have participated in media broadcasts including:
`
`
` Channel 4 Dispatches - The Truth About Beauty Creams
` Daily Mail - Aqueous Cream and eczema
`Irish Times - Paracetamol
`
`
`
`My laboratory has hosted numerous Erasmus students, Visiting Scientists from industry and
`students or academics from universities who wish to establish topical and transdermal research
`centres (India, Iran, Iraq, Japan, Lithuania, Malaysia, Pakistan, South Africa).
`
`12. Enabling activity
`
`2006 - 2011 External examiner for the M.Sc. in Drug Delivery and the M.Sc. in Drug Design
`taught programmes at Aston University.
`
`External examiner for PhD and MSc theses:
` Kings College London
` North West University, South Africa
` Royal College of Surgeons in Ireland
` School of Pharmacy - Queens University of Belfast
` Sheffield Hallam University
` University of Aston
` University of Huddersfield
` University of Hull, UK
` University of Putra, Malaysia
` University of Queensland, Australia
` Veterinary Sciences Division - Queens University of Belfast
`
`
`External examiner for period 2016/17 to 2019/20 for PgD/MSc Pharmaceutical Sciences
`(FT/PT[DL]), University of Coleraine, UK
`
`External examiner for period 2017/2018 to 2020/2021 for the MPharm programme, University of
`Coleraine, UK.
`
`Member of the Chemistry, Pharmacy and Standards Expert Advisory Group of the Medicines and
`Healthcare Regulatory Agency of the United Kingdom (2015 – Present)
`
`Member of the European Medicines Agency Working Group on topical medicines.
`
`Board member of the Academy of Pharmaceutical Sciences of United Kingdom.
`
`
`
`
`
`
`13. Administration
` Tutee for undergraduate students 2006 – Present
` Academic Staff Representative – Joint Staff Negotiating Committee, School of Pharmacy
`2008-2012
` Departmental postgraduate degrees committee representative 2006 – 2012
` Member of UCL Academic Board 2016 – 2018
`
`
`
`
`Page 9
`
`Anacor Exhibit 2045
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00170
`
`

`

`
`
`
`14. Five most significant publications (or other forms of original output) in the last five
`years.
`
`
`
`Skin penetration enhancers.
`Lane ME
`Int J Pharm. 2013 447(1-2):12-21
`*Cited 96 times.
`
`Nanoparticles do not penetrate human skin – a theoretical perspective.
`Watkinson AC, Bunge AL, Hadgraft J, Lane ME.
`Pharm Res. 2013 30(8):1943-6.
`*Despite much controversy the overall findings from the published literature discussed in this
`review confirm that nanoparticles are unlikely to penetrate the skin to any great depth.
`
`Influence of Aqueous Cream BP on corneocyte size, maturity, skin protease activity,
`protein content and transepidermal water loss.
`Mohammed D, Matts PJ, Hadgraft J, Lane ME.
`Br J Dermatol. 2011 Jun;164(6):1304-10.
`*Together with papers from the groups of Prof. Richard Guy (University of Bath), Prof. Michael
`Cork (Sheffield University), this publication has resulted in a reclassification of the use of this
`product as a soap substitute in the British National Formulary.
`
`Influence of penetration enhancer on drug permeation from volatile formulations.
`Santos P, Watkinson AC, Hadgraft J, Lane ME.
`Int J Pharm. 20112 439(1-2):260-8.
`*Fentanyl in transdermal patch form is the most successful transdermal formulation developed to
`date. This publication outlines the development and evaluation of novel transdermal spray
`formulations with comparable skin permeation to commercially available patches.
`
`Opto-Thermal Transient Emission Radiometry (OTTER) to image diffusion in nails in vivo.
`Xiao P, Zheng X, Imhof RE, Hirata K, McAuley WJ, Mateus R, Hadgraft J, Lane ME.
`Int J Pharm. 2011 Mar 15;406(1-2):111-3.
`*First report of the application of this technique to probe solvent diffusion in the nail.
`
`
`
`
`
`
`Page 10
`
`Anacor Exhibit 2045
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00170
`
`

`

`Book
`
` Rathbone, M. J., Hadgraft, J., Roberts, M. S., Lane, M.E. (Eds.) (2008). Modified Release Drug
`Delivery Technology. (2nd ed.). USA: Informa Healthcare.
`Book Chapters
`
` Shah VP, Yacobi A, Lane ME. (2015) Bioequivalence, Quality, and Novel Assessment
`Technologies for Topical Products: Current Challenges and Future Prospects. In: Topical Drug
`Bioavailability: Bioequivalence and Penetration, 2ND Edition (Editors V.P. Shah, H.I. Maibach, J.
`Jenner). Springer. Pages 389-398.
` Xiao P, Abdalghafor H, Lane ME (2014) Membrane solvent penetration measurements using
`contact imaging. In: Advances in Dermatological Sciences. Volume 1. Pp. 355-360. Royal Society
`of Chemistry, London.
` Lane ME. (2012). Emollients and skin barrier function. In Loden, M., Maibach, H. I.
`(Eds.). Treatment of Dry Skin Syndrome. The Art and Science of Moisturizers. (pp. 513-524):
`Springer Heidelberg Dordrecht London.
` Nair AB, Hui X, Lane ME, Murthy SN. (2013) In vitro and in vivo models to evaluate topical nail
`formulations. In:Murthy, S.N., Maibach, H.I. (Eds.). Topical Nail Products and Ungual Drug
`Delivery. Pp. 123-148. CRC Press. Boca Raton, FL, USA.
` Lane ME, Hadgraft J. (2012). Skin permeation assessment: spectroscopic methods. In Benson,
`H. A. E., Watkinson, A. C. (Eds.). Topical and transdermal drug delivery: principles and
`practice (pp.155-166). New York: Wiley.
` Lane ME, Santos P, Watkinson AC, Hadgraft J. (2012). Passive skin permeation enhancement.
`In Benson, H. A. E., Watkinson, A. C. (Eds.). Topical and transdermal drug delivery: principles and
`practice (pp.23-42). New York: Wiley.
` Lane ME, Uchegbu IF, Schatzlein AG. (2010). Nanomedicines from Polymeric Amphiphiles. In
`Torchilin, V., Amiji, M. M. (Eds.). Handbook of materials for nanoscience (Vol. 1 pp.495-514).
`Singapore: Pan Stanford Publishing Pte. Ltd.
` Cork MJ, Moustafa M, Danby S, Vasilopoulos Y, Tazi-Ahnini R, Ward SJ, Hadgraft, J, Lane ME,
`Guy RH. (2009). Skin barrier function in atopic dermatitis. In Rawlings, A. V., Leyden, J. J.
`(Eds.). Skin Moisturization (2nd ed. pp.1-492). New York: Informa Healthcare.
` Wiechers JW, Judefeind A, du Plessis J, Kelly CL, Lane ME, Hadgraft J. (2008). The effect of
`changing the polarity of the stratum corneum on the dermal and transdermal delivery of
`cosmetically active ingredients. In: Wiechers, J. W. (Ed.). Science and application of skin delivery
`systems (pp.1-552). USA: Allured Publishing.
` Lane ME, Hadgraft J. (2007). In vitro – in vivo correlations in transdermal drug delivery. In
`Walters, K. A., Roberts, M. S. (Eds.). Dermal Absorption and Toxicity Assessment (2nd ed. ed.
`pp.1-600). USA: Informa Healthcare.
` Lane ME, Okumu FW, Balausubramanian P. (2007). Editor of: Injections and implants. In Lane,
`M.E., Rathbone, M. J., Roberts, M. S., Hadgraft, J. (Eds.). Modified Release Drug Delivery
`Technology (2nd ed. ed. Vol. 184 pp.123-132). USA: Informa Healthcare.
` Lane ME, Hadgraft J. (2013) Penetration enhancers solvents and the skin. In: Fahr, A,
`Douromis, D. (Eds). Drug delivery strategies for poorly soluble drugs. Wiley, New York. 359-371.
` Lane ME, Watkinson AC, Hadgraft J. Editor of: Dermal and Transdermal Drug Delivery. In Lane,
`M.E., Roberts, M. S., Rathbone, M. J., Hadgraft, J. (Eds.). Modified Release Drug Delivery
`Technology (2nd ed. ed. Vol. 184 pp.263-272). Informa Healthcare.
`
`
`
`
`
`
`Page 11
`
`Anacor Exhibit 2045
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00170
`
`

`

`Conference Presentations
` Machado M, Hadgraft J. Lane ME. (2010). A new model for in vitro finite dose permeation
`studies. Journal of Pharmacy and Pharmacology. Wiley. (Vol. 62 pp. 1240-1240). Wiley.
` Ab Hadi, H., Hadgraft, J., Lane, M.E. (2010). Chemical permeation enhancement strategies for
`improved
`topical
`caffeine
`delivery.
`Journal of Pharmacy and Pharmacology. (Vol. 62 pp. 1254-1255). Wiley.
` Lane ME, Mader KT, Hadgraft J, Kazarian SG, Tetteh J, McAuley WJ, Andanson JM. (2010).
`Investigation of skin permeation using ATR-FTIR spectroscopic imaging and multivariate target
`factor analysis. Journal of Pharmacy and Pharmacology (Vol. 62 pp. 1279-1280). Wiley.
` Lane ME, Chavda SJ, Hadgraft J. (2010). Membrane investigations using biophysical methods
`and multivariate target factor analysis. Journal of Pharmacy and Pharmacology. (Vol. 62 pp. 1285-
`1286). Wiley.
` Lane ME, Mohammed D, Hadgraft J. (2010). Metrology of the stratum corneum. Journal of
`Pharmacy and Pharmacology. (Vol. 62 pp.1286-1287). Wiley.
` Lane ME, Vieira R., Anissimov Y, Watkinson AC, Hadgraft J. (2010). Modelling of drug
`permeation in human skin in vitro from finite dose applications. Journal of Pharmacy and
`Pharmacology. (Vol. 62 pp. 1287-1288). Wiley.
` Lane ME, Hadgraft J. Skin: a tortuous problem. (2007). International Journal of Cosmetic
`Science. (Vol. 29 pp. 224-224. Wiley.
` Lane ME, McAuley WJ, Santos P, Hadgraft J. (2006). Determination of the diffusion coefficient of
`cyanophenol in Carbosil membrane using ATR-FTIR spectroscopy. Journal of Pharmacy and
`Pharmacology (Vol. 58 pp. A47-A47). Wiley.
` Lane ME, Corrigan OI, Levis KA. (2004). Ketoprofen-induced permeability changes in the
`perfused rat intestine. AAPS Journal. (Vol. 6 pp. W4282-W4282). Springer.
` Lane ME, Corrigan OI, Levis KA. (2004) Comparison of two methods for assessment of drug-
`induced permeability changes. European Journal of Pharmaceutical Sciences. (Vol. 23 pp.52-52).
`Elsevier
` Lane ME, Corrigan OI, Levis KA. (2004). Pharmacokinetics of amino acid derivatives of
`ibuprofen in the rat. European Journal of Pharmaceutical Sciences. (Vol. 23 pp.70-71). Elsevier.
` Lane ME, Corrigan OI., Levis KA. (2004). Effect of ibuprofen on the rat intestinal permeability
`of GlySar. European Journal of Pharmaceutical Sciences. Elsevier. (Vol. 23 pp. 75-75.
`Elsevier.
` Lane ME, Corrigan OI, Amidon GL, Deasy PB, Landowski CP, Quigley JM. (2004). Synthesis
`and characterization of arginine derivatives of ibuprofen. AAPS Journal. (Vol. 6 pp. T2290-T2290)
`Springer.
` Lane ME, Corrigan OI, Levis KA. (2003). Dependence of ibuprofen absorption on net intestinal
`fluid flux in the rat gut. AAPS Pharm Sci. (Vol. 5 pp. R6081-R6081) Springer.
` Lane ME, Byrne RS, Deasy PB. The use of pororus aluminosilicate pellets produced by
`cryopelletization for sustained drug delivery. AAPS Pharm Sci. (Vol. 5 pp. W5096-W5096. 2003
` Lane ME, Corrigan OI, Hanlon M, Levis KA, Gilmer JF. (2002). Synthesis and characterisation of
`arginine
`derivatives
`of
`non-steroidal
`anti-inflammatory
`drugs
`AAPS Pharm Sci. (Vol. 4 pp. R6124-R6124). Springer.
` Lane ME, Corrigan OI, O'Driscoll CM, Meaney CM, Gubbins RH. (1998). Correlation between
`permeability co-efficients in a perfused rat model and the CaCo-2 cell model. European Journal of
`Pharmaceutical Sciences. (Vol. 6 pp.24-24). Elsevier.
` Lane ME, Corrigan OI, O’Driscoll CM. (1998). Calculation of fractions of insulin absorbed and
`degraded in a perfused rat intestinal model. European Journal of Pharmaceutical Sciences. (Vol. 6
`pp. 96-96) Elsevier.
` Lane ME, Corrigan OI, O’Driscoll CM. (1998). Effects of protease inhibitors on insulin stability and
`absorption in the rat intestine. 4th EUFEPS Congress, Milan, 1taly, 11 European Journal of
`Pharmaceutical Sciences. (Vol. 6 pp. 97-97) Elsevier.
`
`Page 12
`
`Anacor Exhibit 2045
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00170
`
`

`

` Lane ME, Corrigan OI, O'Driscoll CM. (1998). The effects of bile salt fatty acid mixed micellar
`systems on insulin stability and absorption in the rat intestine. 17th Pharmaceutical Technology
`Conference. (Vol. 1 pp.109-120).
` Lane ME, Corrigan OI, O'Driscoll CM. (1994). The relationship between molecular size and
`gastrointestinal permeability. European Journal of Pharmaceutical Sciences. (Vol. 2 pp.187-187).
`Elsevier.
`
`Journal Articles
`Paz-Alvarez M, Pudney PDA, Hadgraft J, Lane ME. Topical delivery of climbazole to mammalian
`skin. 2018 International Journal of Pharmaceutics 549(1-2):317-324.
`Guneri, D., Voegeli, R., Gurgul, S.J., Munday, M.R., Lane, M.E., Rawlings, A.V. A new approach
`to assess the effect of photodamage on corneocyte envelope maturity using combined
`hydrophobicity and mechanical fragility assays. 2018. International Journal of Cosmetic Science
`40(3), pp. 207-216
`Haque T, Rahman KM, Thurston DE, Hadgraft J, Lane ME.Topical delivery of anthramycin II.
`Influence of binary and ternary solvent systems. 2018. European Journal of Pharmaceutical
`Sciences 121:59-64.
`Khan, M.N., Haggag, Y.A., Lane, M.E., McCarron, P.A., Tambuwala, M.M. Polymeric Nano-
`Encapsulation of Curcumin Enhances its Anti-Cancer Activity in Breast (MDA-MB231) and Lung
`(A549) Cancer Cells Through Reduction in Expression of HIF-1α and Nuclear p65 (Rel A). 2018
`Current Drug Delivery (2):286-295.
`McCulloch R, Sattar M, Henderson EM, Lane ME, Bluebond-Langner M. Use of buccal morphine
`in the management of pain in children with life-limiting conditions: Results of a laboratory study.
`2018 Palliative Medicine 32(2):554-558.
`Khan MN, Lane ME, McCarron PA, Tambuwala MM. Caffeic acid phenethyl ester is protective in
`experimental ulcerative colitis via reduction in levels of pro-inflammatory mediators and
`enhancement of epithelial barrier function. 2018 Inflammopharmacology 26(2):561-569
`Taslimi Y, Sadeghipour P, Habibzadeh S, Mashayekhi V, Mortazavi H, Müller I, Lane ME, Kropf
`P, Rafati S. A novel non-invasive diagnostic sampling technique for cutaneous leishmaniasis. PLo
`Negl Trop Dis. 2017 Jul 13;11(7):e0005750.
`Mallandrich M, Fernández-Campos F, Clares B, Halbaut L, Alonso C, Coderch L, Garduño-
`Ramírez ML, Andrade B, Del Pozo A, Lane ME, Calpena AC. Developing Transdermal
`Applications of Ketorolac Tromethamine Entrapped in Stimuli Sensitive Block Copolymer
`Hydrogels. 2017. Pharmaceutical Research 34(8):1728-1740.
`Charbe NB, McCarron PA, Lane ME, Tambuwala MM. Application of three-dimensional printing
`for colon targeted drug delivery systems. 2017 Int J Pharm Investig. 7(2):47-59
`Haque T, Rahman KM, Thurston DE, Hadgraft J, Lane ME. Topical delivery of anthramycin I.
`Influence of neat solvents. 2017 European Journal of Pharmaceutical Sciences 104:188-195
`Koppes SA, Ljubojević Hadžavdić S, Jakasa I, Franceschi N, Riethmüller C, Jurakić Tončic R,
`Marinovic B, Raj N, Rawlings AV, Voegeli R, Lane ME, Haftek M, Frings-Dresen MH, Rustemeyer
`T, Kezic S. Effect of allergens and irritants on levels of natural moisturizing factor and corneocyte
`morphology.2017 Contact Dermatitis 76(5):287-295.
`Goh, C.F., Moffat, J.G., Craig, D.Q.M., Hadgraft, J., Lane, M.E. Nano-thermal imaging of the
`stratum corneum and its potential use for understanding of the mechanism of skin penetration
`enhancer 2017 Thermochimica Acta 655, pp. 278-283
`Haque T, Lane ME, Sil BC, Crowther JM, Moore DJ.In vitro permeation and disposition of
`niacinamide in silicone and porcine skin of skin barrier-mimetic formulations. International Journal
`of Pharmaceutics 520(1-2), pp. 158-162.
`Goh, C.F., Craig, D.Q.M., Hadgraft, J., Lane, M.E.The application of ATR-FTIR spectroscopy and
`multivariate data analysis to study drug crystallisation in the stratum corneum. 2017 European
`Journal of Pharmaceutics and Biopharmaceutics 111, pp. 16-25
`Parisi, N., Matts, P.J., Lever, R., Hadgraft, J., Lane, M.E. Hexamidine salts-applications in skin
`health and personal care products. 2017 International Journal of Cosmetic Science 39(4), pp. 361-
`365
`
`Page 13
`
`Anacor Exhibit 2045
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00170
`
`

`

`International Journal of
`
`Cartner T, Brand N, Tian K, Saud A, Carr T, Stapelton P, Lane ME, Rawlings AV. (2016) Effect of
`different alcohols on stratum corneum kallikrein 5 and phospholipase A2 together with epidermal
`keratinocytes and skin
`irritation.
`International Journal of Cosmetic Science. doi:
`10.1111/ics.12364.
`Raj N, Voegeli R, Rawlings AV, Doppler S, Imfeld D, Munday MR, Lane ME. (2016) A
`fundamental investigation into aspects of the physiology and biochemistry of the stratum corneum
`in subjects with sensitive skin. International Journal of Cosmetic Science. doi: 10.1111/ics.12334.
`Sattar M, Lane ME. (2016) Oral transmucosal delivery of naratriptan. International Journal of
`Pharmaceutics. In Press.
`formulations (ATF).
`topical
`Hadgraft J, Lane ME. Advanced
`Pharmaceutics doi: 10.1016/j.ijpharm.2016.05.065.
`Haque, T., Crowther, J.M., Lane, M.E., Moore, D.J. Chemical ultraviolet absorbers topically
`applied in a skin